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REVIEW ARTICLE OPEN
Raising awareness of bronchiectasis in primary care: overview
of diagnosis and management strategies in adults
James D. Chalmers1 and Sanjay Sethi2
Bronchiectasis is a chronic lung disease characterised by recurrent infection, inﬂammation, persistent cough and sputum
production. The disease is increasing in prevalence, requiring a greater awareness of the disease across primary and secondary care.
Mild and moderate cases of bronchiectasis in adults can often be managed by primary care clinicians. Initial assessments and long-
term treatment plans that include both pharmacological and non-pharmacological treatments, however, should be undertaken in
collaboration with a secondary care team that includes physiotherapists and specialists in respiratory medicine. Bronchiectasis is
often identiﬁed in patients with other lung diseases, such as chronic obstructive pulmonary disease, asthma, and in a lesser but not
insigniﬁcant number of patients with other inﬂammatory diseases, such as rheumatoid arthritis and inﬂammatory bowel disease.
Overall goals of therapy are to prevent exacerbations, improve symptoms, improve quality of life and preserve lung function.
Prompt treatment of exacerbations with antibiotic therapy is important to limit the impact of exacerbations on quality of life and
lung function decline. Patient education and cooperation with health-care providers to implement treatment plans are key to
successful disease management. It is important for the primary care provider to work with secondary care providers to develop an
individualised treatment plan to optimise care with the goal to delay disease progression. Here, we review the diagnosis and
treatment of bronchiectasis with a focus on practical considerations that will be useful to primary care.
npj Primary Care Respiratory Medicine  (2017) 27:18 ; doi:10.1038/s41533-017-0019-9
INTRODUCTION
Non-cystic ﬁbrosis bronchiectasis (referred to as bronchiectasis
throughout) is a chronic lung disease characterised by recurrent
infection, inﬂammation, persistent cough and production of
sputum.1, 2 Bronchiectasis results from permanent dilation of the
airways.3 The primary insult is often unknown, but pathological
changes in response to Cole’s vicious cycle hypothesis4, 5 are
thought to be responsible for disease progression (Fig. 1).
Causes may include post-infective injury (previous bacterial
or viral infections), congenital defects of the mucociliary clearance
such as primary ciliary dyskinesia (PCD) or immune deﬁciency.1, 2, 5, 6
A listing of possible causes is shown in Table 1, although often the
underlying cause is undetermined.1, 2, 7–14 Where the cause is not
identiﬁed, patients are classiﬁed as having ‘idiopathic’ bronchiec-
tasis. Because prior infections are common causes of bronchiec-
tasis,2, 15 recent guidelines suggest asking patients about previous
respiratory infections, including previous tuberculosis, to establish
possible linkage with the onset of bronchiectasis symptoms.2 In
Lady Windermere syndrome,16, 17 a syndrome named for a
character with a chronic voluntarily suppressed cough in the Oscar
Wilde play Lady Windermere’s Fan,18 bronchiectasis is thought to
be caused by chronic Mycobacterium avium complex or other
pulmonary non-tuberculous mycobacteria (NTM) infection.19 It is
more prevalent in tall, lean, middle-aged women than it is in the
general population.19
Bronchiectasis can also result from rare congenital defects
such as PCD, in which the epithelial cell motor cilia are
dysfunctional, resulting in mucus accumulation.20, 21 Airway
obstruction from the mucus and subsequent inﬂammation and
bacterial infection contribute to development of bronchiectasis.20, 21
Other rare genetic causes associated with bronchiectasis
have recently been reviewed in detail,22 and include Williams-
Campbell syndrome (a cartilage deﬁciency), Mounier-Kuhn
syndrome (tracheobronchomegaly), common variable immune
deﬁciency (hypogammaglobulinaemia), inherited connective
tissue disorders, α1-antitrypsin deﬁciency and yellow nail syndrome.
Bronchiectasis prevalence estimates vary by region and increase
with age but suggest that bronchiectasis is a relatively common
disease. Prevalence estimates in the United States, United
Kingdom and New Zealand are variable owing to differences
in diagnostic techniques and methods2, 13, 23–26; recent estimates
range from 370 per 100,000 persons to 566 per 100,000 persons.13, 24
These estimates also may appear to be increasing owing to
improved diagnosis and recognition, including wider use of high-
resolution chest computed tomography (HRCT) scans.13, 27 To put
the prevalence in context, these estimates suggest there may be 1
patient with bronchiectasis for every 20 patients with chronic
obstructive pulmonary disease (COPD) in Western countries.
Bronchiectasis is commonly found in patients with a diagnosis
of COPD11 and asthma.28, 29 Coexistence of bronchiectasis with
HIV, rheumatoid arthritis, inﬂammatory bowel disease and
pulmonary ﬁbrosis also has been shown.13, 28 A high awareness
of this overlap is needed for primary care physicians to identify
patients with bronchiectasis, as symptoms can be easily dismissed
as part of the underlying disorder.
The aim of this manuscript is to provide a focused review of
bronchiectasis and its management in adult patients for the
general practitioner or primary care physician. Guidelines for
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treatment of bronchiectasis are available from the British
Thoracic Society,2, 30 the Thoracic Society of Australia and New
Zealand25, 31 and SEPAR (Spain),32 but not in the United States.
This review considers these guidelines, along with newly
published information.
CLINICAL PRESENTATION—WHEN TO SUSPECT
BRONCHIECTASIS
A 66-year-old lady presents with a chest infection associated with
cough productive of green sputum and increasing shortness of
breath. She had never smoked and has no relevant past medical
history. Chest x-ray shows no abnormality. She is treated with
antibiotic therapy by her primary care physician and improves.
She attends again a few months later with worsening productive
cough. Her primary care physician notes that she has had several
courses of antibiotics for chest infections over the previous 3
winters and has reported a chronic productive cough on a daily
basis for the past 3 years.
In new patients or those that do not have an established
diagnosis, one of the most common core symptoms is a persistent
cough (>90% of patients), often producing large quantities of
mucoid (white or clear) or purulent (dark yellow, green or brown)
sputum2 (Table 2). Adults may have a history of symptoms over
many years. Recurrent respiratory tract infections also raise the
possibility of bronchiectasis, and patients may take a long time to
recover from chest infections or require multiple courses of
antibiotics before symptoms fully resolve. Dyspnoea is present in a
high proportion of cases, with frequent haemoptysis in severe
disease. These symptoms can be variable across patients, with
some having symptoms daily and others only having symptoms
during exacerbations.5 The longstanding textbook teaching of
bronchiectasis patients with widespread crackles, digital clubbing
and cachexia is now rarely seen.
Diagnosis may be difﬁcult when a patient has already received a
diagnosis of another chronic respiratory disease such as COPD or
asthma. Furthermore, considerable diagnostic confusion exists
between bronchiectasis, asthma and COPD. Patients with primary
bronchiectasis are often ﬁrst labelled as asthma and COPD. Further
adding to this complexity is the occurrence of secondary
bronchiectasis in patients with asthma and COPD, and the
coexistence of these common disorders in the same patient. A
thorough clinical evaluation is essential and often the best
diagnostic tool to determine the primary condition/s and manage
accordingly. Bronchiectasis should be suspected in patients when
there is a poor response to standard therapy, when unusual
pathogens are isolated from sputum or when patients do not have
a typical clinical history of COPD (e.g., absence of smoking history
or young age of onset). In addition, patients with asthma may
develop bronchiectasis associated with an immunological reaction
to Aspergillus, known as allergic bronchopulmonary aspergillosis
(ABPA).2 Such patients present with a history of asthma that is
poorly controlled, often with the production of large volumes of
sputum or plugs. Therefore, bronchiectasis and ABPA should be
considered as a potential contributor to severe asthma or poor
asthma control.
HOW TO DIAGNOSE BRONCHIECTASIS
Primary care
The majority of respiratory tract infections seen in the primary care
setting are self-limiting and do not require further investigation. In
addition, the majority of patients with a chronic cough will not
have bronchiectasis. In one study of 266 patients with chronic
cough lasting longer than 8 weeks referred to a secondary care
cough clinic and who completed follow-up, most patients had
positive outcomes and did not receive a bronchiectasis diag-
nosis.33 The largest group of patients (29%) had asthma that was
demonstrated by bronchodilator reversibility. Gastro-oesophageal
reﬂux disease (GORD) related cough was noted in 22% and most
of these patients were sensitive to proton pump inhibitor
Fig. 1 Vicious cycle hypothesis of bronchiectasis4, 5




Undetermined (idiopathic bronchiectasis) 30–53
Previous infection–bacterial or viral 33–42
Aspiration/inhalation injury 2–4
Congenital defect of large airway (e.g., Mounier-Kuhn
syndrome)
<1
Immune deﬁciency (hypogammaglobulinaemia) 1–8
Primary ciliary dyskinesia 1–17
Connective tissue disease/rheumatoid arthritis/
Sjögren’s syndrome/systemic sclerosis
3–6
Cause or comorbid condition
COPDa 4–69
Asthmaa 17.5–43.0
Allergic bronchopulmonary aspergillosis (associated
with asthma)
1–7
Inﬂammatory bowel disease 1–2
Non-tuberculosis mycobacterial infection 0.7–34.0
Data from Aliberti et al.,8Agusti et al.,7Chalmers and Hill,1 Fowler et al.,9
Gupta et al.,10 Ni et al.,11 Park and Olivier,12 Pasteur et al.,2 Quint et al.13
COPD chronic obstructive pulmonary disease
aWhether COPD and asthma are the underlying cause of bronchiectasis, or
are associated conditions, is often not clear. Non-tuberculous Mycobacteria
and allergic bronchopulmonary aspergillosis are thought to be both
causes and consequences of bronchiectasis
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treatment. Angiotensin converting enzyme inhibitor (ACEi)-
induced cough was present in 14% and resolved on withdrawal
of the ACEi. Only one patient had a diagnosis of bronchiectasis.
Indicators of possible bronchiectasis are sputum production,
which is often absent with GORD, cough variant asthma or cough
hypersensitivity, and episodes of respiratory tract infections, which
are also uncommon with these disorders. Fevers or night sweats
with a chronic cough are unusual in bronchiectasis and suggest
pulmonary tuberculosis or pulmonary non-tuberculous Mycobac-
terial disease in the appropriate clinical context.
Bronchiectasis should be considered as a possible diagnosis
where respiratory tract infections are severe, persistent, unusual or
recurrent (represented by the helpful acronym SPUR). Patients
with suspected clinical signs and symptoms of bronchiectasis
should be evaluated by a thorough clinical examination to rule out
other possible causes and a sputum sample should be sent for
microbiological analysis.2, 25
Haemophilus inﬂuenzae, Pseudomonas aeruginosa, Streptococcus
pneumoniae and Moraxella catarrhalis are among the most common
pathogens isolated from patients with bronchiectasis.2, 34, 35
Standard bacterial cultures will not identify some important
bronchiectasis-associated pathogens such as NTM, but these can
be excluded by requesting speciﬁc cultures for Mycobacteria.
Negative sputum cultures do not exclude a diagnosis of
bronchiectasis. Sending samples when patients are clinically ‘well’
is important, as culture positive samples with chest infections are
common in many conditions, but a culture positive sputum
sample when the patient is well increases the likelihood that the
patient has bronchiectasis.
Chronic colonisation with P. aeruginosa occurs in many patients
and is associated with more severe disease.2, 36 In a recent
systematic review,37 which included a meta-analysis of 21 studies,
mortality for bronchiectasis patients with P. aeruginosa colonisa-
tion was higher (pooled odds ratio of 2.95, P < 0.0001) than in
patients without colonisation. In patients with P. aeruginosa,
mortality was 7.7% at 1 year and 30 to 50% at 5 years.37 In
contrast, mortality for bronchiectasis patients without P. aerugi-
nosa was 0% at 1 year and 9 to 15% at 5 years. Hospital admission
rates were signiﬁcantly increased in those with P. aeruginosa, as
were exacerbation rates (those with P. aeruginosa infection had an
average of 1 additional exacerbation per patient per year than
those without). P. aeruginosa was also associated with a worsened
quality of life.37 Isolation of P. aeruginosa in a new patient or for
the ﬁrst time in a patient with recurrent respiratory tract infections
should be promptly referred to secondary care for antibiotic
treatment.2
Knowing which pathogen is present, if any, will help determine
the most effective antibiotic treatment. However, isolation of a
pathogen does not require treatment if the patient is well, as
many patients are chronically infected with organisms that will not
be eradicated by repeated short courses of oral antibiotics.6, 38
A regular chest x-ray may be insensitive to the changes caused
by bronchiectasis, as in the clinical example above.39 Although an
HRCT scan of the chest is the radiological investigation of choice in
the diagnosis of bronchiectasis,2, 30 it may also be identiﬁed using
a standard CT scan. Bronchial dilation (luminal diameter greater
than accompanying pulmonary artery/lack of tapering) is the
deﬁning feature (Fig. 2).2, 25, 30 Bronchial wall thickening also may
be present.2 If HRCT is not indicative of bronchiectasis, then the
diagnosis can be excluded.
In some cases, radiological evidence for bronchiectasis will be
found in patients without overt symptoms. Radiological evidence
of asymptomatic bronchiectasis should be investigated to
determine if a causal event might explain the ﬁnding. This has
been reported to occur in patients with underlying rheumatoid
arthritis or humoral immune deﬁciency.2 However, it should be
emphasised that bronchiectasis is a clinical diagnosis, supported
by imaging, rather than a condition identiﬁed by imaging alone.
Lung function should be evaluated using spirometry,2, 25, 30
assessing forced expiratory volume in the ﬁrst second (FEV1),
forced vital capacity and peak expiratory ﬂow.2 Although up to
80% of adult patients with bronchiectasis in secondary care will
exhibit airﬂow obstruction, some show no reduction in airﬂow and
spirometry may be completely normal.2 Presence of reduced FEV1
is highly predictive of mortality, hospital admission, exacerbation
frequency and worse quality of life;40 however, it is important to
emphasise that airﬂow reduction is a marker of severity, but it is
not useful for diagnosis. For example, in one study of 608 patients
with conﬁrmed bronchiectasis, 49.5% had airﬂow obstruction,
18.8% had restrictive spirometry, yet 31.7% had normal
spirometry.40
A 71-year-old lady presents with 2 years of worsening cough,
sputum production and 5 chest infections in the past year
requiring antibiotics. She is an ex-smoker, has a previous history
of asthma and is treated with an inhaled corticosteroid. She also
has a history of rheumatoid arthritis, but has had well controlled
joint disease for several years. Sputum culture is positive for
Table 2. Symptoms/signs of bronchiectasis






Asthma or COPD unresponsive to usual treatment
Additional signs and symptoms
Coarse crackles on auscultation (often absent)
Chronic rhinosinusitis
Chest discomfort
Fatigue and weight loss
Signs associated with underlying disorders (e.g., rheumatoid arthritis, yellow nail syndrome, connective tissue disease)
Pasteur et al.2 and Chalmers et al.5
COPD chronic obstructive pulmonary disease
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H. inﬂuenzae. The primary care physician suspects bronchiectasis
and refers the patients for a high resolution CT scan. This shows
bilateral lower lobe bronchiectasis.
The above example illustrates the difﬁculties of identifying and
managing bronchiectasis in the context of multiple comorbidities.
The presentation could relate to poorly controlled asthma,
undiagnosed COPD, immunosuppression resulting from tumour
necrosis factor antagonist therapy, Mycobacterial infection or
bronchiectasis. The diagnosis of bronchiectasis is easily missed in
such patients.
Consequently, recognition of comorbid/associated conditions
associated with bronchiectasis is very important (Table 1).2, 13, 41, 42
Prevalence of bronchiectasis in patients with COPD has been
found to range from a low of 4% (ref. 7) to as high as 69%, with
mean prevalence of 54% in a recent systematic literature review.11
In many studies in patients with COPD, the presence of
bronchiectasis was associated with increased presence of P.
aeruginosa and other pathogenic microorganisms in sputum,
reduced lung function, greater sputum production, more frequent
exacerbations and increased mortality versus those with COPD
alone.11, 43 Patients with some non-pulmonary diseases (e.g.,
rheumatoid arthritis, sarcoidosis, ulcerative colitis/inﬂammatory
bowel disease) can have recurrent lung infections and may have
concurrent bronchiectasis.44, 45 As shown in Table 1, the
prevalence estimates for concurrent bronchiectasis in those with
non-pulmonary diseases can range from 1 to 2% for inﬂammatory
bowel disease to as high as 6% for rheumatoid arthritis.
Referral to secondary/specialist care
Most patients with a diagnosis of bronchiectasis will be referred to
secondary/specialist care for an assessment even if care is
subsequently maintained by the primary care team. Specialist
care may be necessary to investigate and conﬁrm underlying
causes, as speciﬁc treatment plans, including antibiotics, canvary
depending on the underlying cause. Specialists will perform and/
or interpret tests that may not be available in primary care, such as
HRCT in some places, immunoglobulin classes (IgG, IgA, IgM, Total
IgE), IgE speciﬁc to Aspergillus fumigatus and Aspergillus precipi-
tins.30 More specialised testing in certain populations, such asα1-
antitrypsin testing,5 functional antibody responses to vaccination
or a myeloma screening also might be performed. Testing
concentrations of nasal nitric oxide20 to exclude ciliary dyskinesia
may be required, but is generally available only at specialist
centres.46 Adult diagnosis of cystic ﬁbrosis may be made in
patients presenting with apparent ‘non-CF’ bronchiectasis. The
diagnosis should be suspected in patients <50 years of age with P.
aeruginosa or S. aureus infection, male infertility or other
extrapulmonary features. Sweat test and/or genotyping for
common cystic ﬁbrosis transmembrane conductance regulator
mutations should be performed in these patients.47–50
Determining severity of disease. Bronchiectasis has a highly
variable impact on patients. Patients with mild disease, as deﬁned
by a lower number and intensity of symptoms, may not produce
sputum except during exacerbations, and will be in otherwise
good health. Sputum in patients with mild disease is often mucoid
(white or clear), sputum cultures are negative, and lung function is
well preserved. Patients with moderate disease often have
persistent symptoms in spite of standard care and may require
antibiotic therapy between exacerbations. In contrast, patients
with severe disease typically will have large volumes of purulent
sputum even when ‘well’, have reduced lung function and
frequent exacerbations and have sputum cultures positive for a
range of bacteria including P. aeruginosa.
Exacerbations have a severe impact on quality of life.51 In
addition, the presence of bronchiectasis is associated with an
increase in mortality compared with the general population.13
Care decisions should be based on identifying patients at high risk
of frequent exacerbations, hospital admission and death. Hospi-
talisation is recommended in patients with breathlessness,
circulatory failure/cyanosis, hypoxia, temperature ≥38°C (100.4°F),
requirement for intravenous therapy or massive haemoptysis.2
The bronchiectasis severity index has recently been developed
and extensively validated and may enhance the ability of physicians
to predict outcomes and better manage patient care.40 The index
uses clinical data (age, body mass index, FEV1%, hospitalisation for
severe exacerbations, exacerbation number per year, Medical
Research Council dyspnoea score, P. aeruginosa colonisation,
colonisation with other organisms and radiological severity [≥3
lobes involved]) to derive a numerical score (see the online tool:
http://www.bronchiectasisseverity.com). Bronchiectasis severity
index scores can be used to predict the likelihood of one or more
of the major consequences of the disease: mortality, frequency of
exacerbations, hospital admissions and deterioration of health-
related quality of life. The FEV1, age, colonisation, extension on CT
and dyspnoea (FACED) score also has been developed speciﬁcally
to predict mortality in patients with bronchiectasis and is based on
ﬁve clinical variables (FEV1%, age, Pseudomonas colonisation,
radiological severity [≥2 lobes involved] and Medical Research
Council dyspnoea score).52 Both scoring systems predict long-term
mortality, but FACED does not reliably reﬂect severity of disease in
terms of exacerbations and quality of life.53–55 Those at highest risk
require specialist care and intensive follow-up and/or aggressive
therapy. Neither of these scoring systems has been developed for
use in primary care, and both require steps such as evaluating lobar
involvement on CT that are not commonly performed during
primary care assessment. Formal scoring can be useful for clinical
management, but at a minimum we would recommend that
primary care physicians are aware that frequent exacerbations,
hospital admissions, lower FEV1%, signiﬁcant breathlessness and
Fig. 2 Example high-resolution chest computed tomography
images of bronchiectasis. a Cylindrical bronchiectasis; b longitudinal
or varicose bronchiectasis
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the presence of P. aeruginosa and other pathogens are markers of
worse prognosis.
OVERALL GOALS OF TREATMENT
The main goals of treatment are to reduce exacerbations, preserve
lung function and improve the patient’s quality of life. A disease
management schematic is shown in Fig. 3. Patients with
bronchiectasis should be instructed in how to improve airway
clearance using physiotherapy techniques at home or at a
physiotherapy clinic. Treatments, both pharmacological and non-
pharmacological, should focus on reducing inﬂammation and
preventing exacerbations. Because bronchiectasis involves a
permanent change in lung structure, the condition is chronic
and the patient’s quality of life may be severely impacted. Care is
best managed by a stepwise multidisciplinary team approach,
including respiratory/chest physiotherapy.5
Primary care management
Some management principles are common to all patients with
bronchiectasis and include the requirement for good education
about the disease, annual vaccination against inﬂuenza and
vaccination against S. pneumoniae. Patients that are breathless will
beneﬁt from pulmonary rehabilitation as is the case with other
respiratory disorders, and patients should be encouraged to
exercise. Smoking cessation should be strongly advocated for the
minority of patients that continue to smoke (up to 18% of patients
with bronchiectasis are reported to be current smokers).40
Speciﬁc management strategies for bronchiectasis depend on
the underlying severity and cause of disease. Patients with mild or
moderate bronchiectasis are often managed and monitored in the
primary care setting. Patients with mild bronchiectasis usually will
not require prophylactic antibiotic therapy, but those with sputum
production should perform daily physiotherapy between and
during exacerbations.5 Patients with moderate bronchiectasis
patients will typically have persistent symptoms in spite of
standard care and may require prophylactic long-term antibiotic
therapy as well as adjunctive treatments and strategies to
promote mucus clearance (see sections below on Secondary care
management and Chest physiotherapy/respiratory therapy).5
In the primary care setting, management should focus on
monitoring the disease and implementing techniques and
procedures to minimise disease progression and maximise
equality of life. Regular clinic visits will allow the primary care
provider to coordinate care with specialists and refer the patient
Fig. 3 Bronchiectasis disease management. COPD, chronic obstructive pulmonary disease
Table 3. Key questions to ask at each visit
Key points and questions for each visit
Are disease symptoms controlled?a
Is the patient performing pulmonary physiotherapy?
What is the frequency of exacerbations?
How are we going to treat the next exacerbation (requires recent sputum sample and knowledge of antibiotic allergies/sensitivities)?
Treatment should be based on previous sputum culture
Important to send an additional sputum sample for analysis at the start of an exacerbation
Treat for 14 days
When was last time that sputum was analysed (twice per year is recommended)?2
Positive culture for Pseudomonas aeruginosa, particularly for a new ﬁnding, should prompt review and often referral to secondary care
Are there any signs of deterioration?
aKey symptoms are cough, sputum production and breathlessness
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to the appropriate specialist, as needed. Key considerations for the
primary care provider to assess at each visit are outlined in
Table 3. Regular tracking of exacerbations and symptoms allows
the patient to learn more about managing his or her disease and
helps to keep the care plan up-to-date. Regular monitoring of
sputum56 (ideally twice per year) will identify the emergence of
new pathogens or the development of antibiotic resistance. The
previous sputum results can be used to guide future antibiotic use
for exacerbations.
Spirometry is a key pulmonary function test used to assess lung
function and should be performed at least annually, and
preferably at each clinic visit in patients with severe bronchiec-
tasis.2, 5, 10, 25, 31 Signiﬁcant worsening over time in pulmonary
function indicates worsening disease and should drive an
intensiﬁcation in treatment.
The discussion between the primary care provider and patient
during these routine visits provides an opportunity for ongoing
patient education, a key component of disease management.
Educating the patient regarding the disease will ensure that he or
she understands the clinical approach and management plan,
including the importance of sputum analysis.2 It is crucial that
patients are able to recognise an exacerbation and how best to
access the medical care team when necessary. Knowledge of
airway physiotherapy/airway clearance techniques will help
reduce the impact of exacerbations and improve quality of life.
In a study to determine compliance with a bronchiectasis
treatment program in 75 patients, only 53% were found to be
compliant with medical treatment and only 41% were compliant
with airway clearance techniques.57 Improving compliance with all
aspects of recommended therapy is, therefore, a key goal of
enhanced patient education. Indeed, the beneﬁts of patient
education have been demonstrated by expert patient self-
management programs that promote action planning, role
modelling, problem solving, reinterpretation of symptoms and
decision making.58
Exacerbation monitoring/management. An exacerbation can be
deﬁned as a signiﬁcant worsening of symptoms over several days,
which may include an increase in the frequency of cough,
shortness of breath, increase of sputum volume, viscosity and/or
purulence.2 In the outpatient setting, assessments of exacerba-
tions should include the history, a clinical examination, a sputum
sample for culture prior to beginning antibiotic treatment and a
review of previous sputum microbial analyses.2
Medications should be chosen based on current and previous
bacteriological results.2, 5, 31 For exacerbations that are not severe,
oral antibiotics are appropriate. Standardised courses of antibiotics
(14 days) are recommended for all patients with exacerbations
owing to the higher airway bacterial loads observed in
bronchiectasis. Antibiotic prescribing is variable in the United
States and among European countries.59–61 Recent guidelines
suggest that coordinated efforts to develop antibiotic stewardship
programs can help to minimise the development of antibiotic
resistance.59, 60
Patients requiring intravenous antibiotics include those with
severe infections requiring hospital admission, patients with
organisms resistant to oral antibiotic agents (most frequently P.
aeruginosa resistant to ciproﬂoxacin or other multi-drug resistant
Gram-negative organisms) or patients who have failed to improve
with 14 days of targeted oral antibiotics. Patients with respiratory
failure, confusion, haemodynamic instability or large volume
haemoptysis will require admission to hospital. Small volume
haemoptysis is relatively common in bronchiectasis and may
simply require antibiotic therapy. Patients experiencing haemop-
tysis for the ﬁrst time should be evaluated by a specialist and
patients with large volume haemoptysis (e.g.,>100 ml), or
haemoptysis with hypoxaemia or haemodynamic instability
should be referred to hospital.
Although most often administered to hospitalised patients,
intravenous antibiotics have been shown to be effective and safe
when administered at home, after proper instruction.62
P. aeruginosa eradication. P. aeruginosa is a special case because
of its strong impact on prognosis. When P. aeruginosa is isolated
for the ﬁrst time in patients with bronchiectasis most international
guidelines recommend attempting to eradicate the organism
when isolated for the ﬁrst time in sputum. Our recommendation
for primary care is to send sputum samples for stable patients at
least once per year, and preferably more often. In the event of a
ﬁrst positive sample for P. aeruginosa, patients should send a
further sample for culture, and treat with oral ciproﬂoxacin 750mg
twice daily for 14 days. A repeat sputum sample should be sent
after antibiotics to determine if the treatment has been successful
and the patient should be referred to a specialist who will
determine whether to add intravenous or inhaled antibiotics to
the regime.2
Inhaled bronchodilators and corticosteroids. Although there is
limited evidence, it is reasonable to treat patients with signiﬁcant
breathlessness with inhaled bronchodilators, such as combined
long-acting β-agonists and anti-muscarinics. This is particularly the
case when airﬂow obstruction is present.
Recent recommendations suggest no role for inhaled corticos-
teroids in bronchiectasis unless the patient has coexisting asthma
or COPD.2, 5, 31 In a recent reviews, these agents have not been
shown to have signiﬁcant beneﬁcial effects on lung function or
exacerbation frequency in bronchiectasis patients without asthma
or COPD.5, 51
Secondary care management
Once a patient is diagnosed, he or she should be referred to
secondary care for assessment and to help determine the
underlying cause of the disease as described in the Introduction.
Secondary care physicians in most countries will provide the initial
disease education and provide access to chest physiotherapy.
Patients with immune deﬁciency can often be treated by
immunoglobulin replacement therapy under the care of an
immunologist.2 Specialists should also be involved in the treatment
of patients with ABPA, who will nearly always have asthma,
elevated total and Aspergillus-speciﬁc IgE and IgG-mediated
immunological responsiveness. Treatment of ABPA involves
prolonged treatment with oral corticosteroids. Antifungal agents
may also be used as steroid-sparing agents.2, 5, 63 Secondary care
teams are necessary when managing patients with severe
bronchiectasis requiring long-term oxygen therapy and/or persis-
tent symptoms requiring oral and/or inhaled antibiotics.5, 30
Specialist care is also required if chronic P. aeruginosa, opportunist
mycobacteria (NTM), methicillin-resistant S. aureus colonisation
or ABPA occur,2, 5, 30 and for patients with deteriorating lung
function, as treatment for these conditions will often require
specialised combinations of antibiotics/antifungals and/or robust
monitoring.2, 63 Some aetiologies, such as rheumatoid arthritis and
PCD, are associated with a more severe course and these patients
will usually be managed in secondary care.
Recent controlled trials have provided evidence that macrolide
antibiotics (azithromycin, erythromycin) can reduce exacerbation
frequency and improve quality of life.5, 51, 63, 64 It is important to
note, however, that long-term treatment can lead to the
development of antibiotic resistance.64 As use of long-term
macrolides is increasingly common, it is important for primary
care physicians to be aware of the potential complications and
consequences of macrolide treatment. Up to 20% of patients will
develop gastrointestinal side effects with macrolides,65, 66 and this
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is more common if higher doses are used. If this becomes
troublesome, a dose reduction or change to an alternative oral
antibiotic may be needed. Macrolides can cause hearing loss67
and this may initially present with tinnitus. This is usually
reversible but macrolides should be discontinued immediately if
tinnitus is reported. Macrolides can prolong the QT interval68 and
so should not be co-prescribed with other drugs that prolong the
QT interval.
Inhaled formulations of antibiotics deliver higher concentrations
of a drug to sites of infection within the airway than with delivery
by oral or intravenous routes. A meta-analysis of nine trials
indicated that inhaled formulations reduced sputum bacterial
load, increased the eradication of P. aeruginosa, reduced exacer-
bations and decreased health-care utilisation.69 It must be
emphasised, however, that as yet, no inhaled antibiotics have
been approved by regulatory agencies for treatment of bronch-
iectasis. Several inhaled antibiotics are licensed for cystic ﬁbrosis
bronchiectasis, but use of data from antibiotic trials in patients
with cystic ﬁbrosis are not always directly translatable to non-
cystic ﬁbrosis bronchiectasis. The most common adverse effect of
inhaled antibiotics is bronchospasm. As a result, it is recom-
mended that inhaled antibiotics are always initiated in secondary
care, and a test dose is administered in a controlled environment
(e.g., hospital ward or outpatient clinic setting) to ensure the
patient does not experience an adverse reaction.
Chest physiotherapy/respiratory therapy. Physiotherapy techni-
ques are recommended as non-pharmacological methods for
mucus clearance, and should be tailored to the individual patient
through input from a specialist in physiotherapy where possible.
The most frequently used technique in Europe is the active cycle
of breathing technique (ACBT).70 In a systematic review and meta-
analysis, ACBT was shown to be more effective in reducing
sputum volume than other methods.71 ACBT includes breathing
control (tidal breathing at a normal rate), thoracic expansion
exercises (deep breathing exercises), forced expiration of 1 or 2
huffs, followed by more breathing control. The huffs assist in
clearing secretions in the larger upper airways. These methods can
be viewed online by searching www.youtube.com for ‘ACBT
breathing technique.’ Several excellent physiotherapist-narrated
videos are available demonstrating this technique.
Several oscillatory positive expiratory pressure devices are also
available to assist with airway clearance, including the Flutter,
Shaker and Acapella, which are handheld devices that use exhaled
breath to create oscillating positive expiratory pressure to help
clear mucus.72, 73 The Lung Flute is a small self-powered handheld
audio device that produces a low frequency acoustic wave with
moderately vigorous exhalation, rather than oscillatory back
pressure, to increase mucus clearance.74 The majority of patients
can manage their chest clearance without requiring devices, but
these may be helpful as adjuncts under the supervision of
specialist chest physiotherapists. It is recommended that patients
with severe symptoms, frequent exacerbations or those experien-
cing difﬁculty with expectoration are reviewed regularly by a
specialist physiotherapist.
Surgical options. Removal of portions of damaged lung may be
considered in patients with severe bronchiectasis who have failed
medical therapy.2 In patients with localised disease, recent reviews
suggest that the removal of the permanently damaged areas of
the lung can result in signiﬁcant symptom resolution and an
improved quality of life.75, 76 In a meta-analysis of 38 studies
covering 5541 patients who had surgical resection for manage-
ment of bronchiectasis, operative morbidity and mortality rates
were 16.7% and 1.5%, respectively.76
Treatment algorithm for the deteriorating patient
A major challenge in the care of patients with bronchiectasis in
the primary care setting is managing those whose condition is
deteriorating. This situation may require input from an expanded
team of specialists to intensify and reﬁne the treatment plan.
Figure 4 illustrates an algorithm for advancing the treatment plan
for typical patient scenarios of deterioration in their condition,
which reﬂects the authors’ clinical experiences. Deterioration is
deﬁned as an increase in the number of exacerbations (>2 per
year), hospital admissions, rapidly declining FEV1 and new
isolation of P. aeruginosa in sputum associated with worsening
of symptoms. It is essential for primary care physicians to be
Fig. 4 Considerations for the management of bronchiectasis in a
patient with worsening symptoms in primary care. ABPA, allergic
bronchopulmonary aspergillosis; BSI, bronchiectasis severity index;
HRCT, high-resolution chest computed tomography; NTM, non-
tuberculous Mycobacteria
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conﬁdent in identifying patients such as those that require referral
or re-referral to secondary care and intensiﬁed therapy.
CONCLUSIONS
Bronchiectasis is a complex chronic disease, often resulting in
disability and impaired quality of life. Patient education and
compliance with care providers’ recommendations are key to
successful disease management. Progress in determining best
practices and treatments will be aided by patient recruitment into
recently developed patient registries in the United States and
Europe.5, 51 These registries will encompass the experiences of
many more and varied patients than can be included in individual
clinical trials. They encourage international collaborations and can
help drive research with the overall goal of improving clinical
care.51
Although mild and moderate bronchiectasis usually can be
managed in the primary care setting, collaboration with specialists
to develop an individualised patient management plan would
provide advanced planning should the patient’s condition worsen.
Those with more advanced disease who require long-term
antibiotic therapy should be referred to secondary care.
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